Literature DB >> 30224524

Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis.

Mahdi Abastabar1, Iman Haghani1, Tahereh Shokohi1, Mohammad Taghi Hedayati1, Seyed Reza Aghili1, Ali Jedi2, Sulmaz Dadashi2, Shafigheh Shabanzadeh1, Tahereh Hosseini2, Narges Aslani3, Jacques F Meis4,5, Hamid Badali6,7.   

Abstract

The in vitro activity of tavaborole, an FDA-approved antifungal drug, was compared to that of four antifungal agents against 170 clinical fungal isolates originating from patients with onychomycosis. Tavaborole had low activity against all isolates compared to itraconazole, terbinafine, and fluconazole, the principal choices for treatment of onychomycosis. Thus, it appears that tavaborole is not a candidate for the treatment of onychomycosis due to Candida species, Aspergillus species, and dermatophytes.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  antifungal; onychomycosis; tavaborole

Mesh：

Substances：

Year:  2018        PMID： 30224524      PMCID： PMC6256807          DOI： 10.1128/AAC.01632-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  33 in total

Review 1.  Onychomycosis in the 21st Century: An Update on Diagnosis, Epidemiology, and Treatment.

Authors:  Aditya K Gupta; Sarah G Versteeg; Neil H Shear
Journal:  J Cutan Med Surg       Date:  2017-06-22       Impact factor: 2.092

2.  Restriction analysis of β-tubulin gene for differentiation of the common pathogenic dermatophytes.

Authors:  Mahdi Abastabar; Hossein Mirhendi; Ali Rezaei-Matehkolaei; Mohammad Reza Shidfar; Parivash Kordbacheh; Koichi Makimura
Journal:  J Clin Lab Anal       Date:  2014-01-06       Impact factor: 2.352

3.  In vitro combination of voriconazole with micafungin against azole-resistant clinical isolates of Aspergillus fumigatus from different geographical regions.

Authors:  Hamed Fakhim; Afsane Vaezi; Eric Dannaoui; Cheshta Sharma; Bita Mousavi; Anuradha Chowdhary; Jacques F Meis; Hamid Badali
Journal:  Diagn Microbiol Infect Dis       Date:  2018-03-08       Impact factor: 2.803

Review 4.  Epidemiology, clinical presentation and diagnosis of onychomycosis.

Authors:  J Faergemann; R Baran
Journal:  Br J Dermatol       Date:  2003-09       Impact factor: 9.302

Review 5.  Tavaborole - a treatment for onychomycosis of the toenails.

Authors:  Aditya K Gupta; Sarah G Versteeg
Journal:  Expert Rev Clin Pharmacol       Date:  2016-07-14       Impact factor: 5.045

Review 6.  Onychomycosis: Current trends in diagnosis and treatment.

Authors:  Dyanne P Westerberg; Michael J Voyack
Journal:  Am Fam Physician       Date:  2013-12-01       Impact factor: 3.292

7.  Epidemiology of onychomycosis in Italy: prevalence data and risk factor identification.

Authors:  Manuela Papini; Bianca Maria Piraccini; Elisa Difonzo; Andrea Brunoro
Journal:  Mycoses       Date:  2015-09-28       Impact factor: 4.377

8.  An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.

Authors:  Fernando L Rock; Weimin Mao; Anya Yaremchuk; Mikhail Tukalo; Thibaut Crépin; Huchen Zhou; Yong-Kang Zhang; Vincent Hernandez; Tsutomu Akama; Stephen J Baker; Jacob J Plattner; Lucy Shapiro; Susan A Martinis; Stephen J Benkovic; Stephen Cusack; M R K Alley
Journal:  Science       Date:  2007-06-22       Impact factor: 47.728

9.  In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates.

Authors:  Nesa Baghi; Tahereh Shokohi; Hamid Badali; Koichi Makimura; Ali Rezaei-Matehkolaei; Maryam Abdollahi; Mojtaba Didehdar; Iman Haghani; Mahdi Abastabar
Journal:  Med Mycol       Date:  2016-04-26       Impact factor: 4.076

10.  Emerging Candida species isolated from renal transplant recipients: Species distribution and susceptibility profiles.

Authors:  Kambiz Diba; Khadijeh Makhdoomi; Elahe Nasri; Afsane Vaezi; Javad Javidnia; Davood Jabbari Gharabagh; Nima Hosseni Jazani; Ali Reza Chavshin; Parisa Badiee; Hamid Badali; Hamed Fakhim
Journal:  Microb Pathog       Date:  2018-09-18       Impact factor: 3.738
View more
  4 in total

1.  In Vitro Resistance and Evolution of Resistance to Tavaborole in Trichophyton rubrum.

Authors:  Diletta Mazzantini; Francesco Celandroni; Marco Calvigioni; Antonella Lupetti; Emilia Ghelardi
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

2.  Evaluation of different DNA extraction methods based on steel-bullet beating for molecular diagnosis of onychomycosis.

Authors:  Marjan Motamedi; Abdulbaqi Amini; Somayeh Yazdanpanah; Mozhgan Mahmoodi; Hossein Khodadadi; Hamidreza Zalpoor
Journal:  J Clin Lab Anal       Date:  2022-08-21       Impact factor: 3.124

Review 3.  Molecular targets for antifungals in amino acid and protein biosynthetic pathways.

Authors:  Aleksandra Kuplińska; Kamila Rząd
Journal:  Amino Acids       Date:  2021-06-03       Impact factor: 3.520

4.  A Mycological and Molecular Epidemiologic Study on Onychomycosis and Determination In Vitro Susceptibilities of Isolated Fungal Strains to Conventional and New Antifungals.

Authors:  Samaneh Halvaee; Roshanak Daie-Ghazvini; Seyed Jamal Hashemi; Sadegh Khodavaisy; Abbas Rahimi-Foroushani; Heidar Bakhshi; Zahra Rafat; Pegah Ardi; Mahdi Abastabar; Mahdi Zareei; Zeinab Borjian-Boroujeni; Hasti Kamali Sarvestani
Journal:  Front Cell Infect Microbiol       Date:  2021-07-15       Impact factor: 5.293
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.